Chengdu Kanghua Biological Products Co. Td Class 1

Chengdu Kanghua Biological Products Co. Td Class 1

SSZSE:300841
47.02
CNY
+0.07
(+0.15%)
1.92EPS
28.38P/E
7.32BMarket Cap
Apr 19Next Earn
Chengdu Kanghua Biological Products Co. Td Class 1
SZSE:300841
(Shenzhen Stock Exchange)

Recent

price

47.02

P/E

ratio

28.38

div

yld

1.08%

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.53
0.69
1.94
5.58
5.48
8.79
9.6
10.8
11.79
10.88
8.97
9.31
Revenue per Share
0.09
0.05
0.55
1.54
1.84
3.45
6.16
4.47
3.81
3.03
1.69
1.99
Basic EPS, GAAP
0.03
0.01
0.63
0.23
1.57
1.98
-1.37
-1.67
3.12
3.25
2.38
- -
Free Cash Flow per Basic Share
- -
- -
0.16
0.06
0.01
- -
0.67
1.02
0.54
2.03
1.05
0.51
Dividend per Share
-1.02
-0.95
1.86
3.63
5.68
14.63
19.78
22.84
26.1
25.93
27.22
28.48
Book Value per Share
-1.19
-1.1
1.73
3.52
5.59
14.46
19.64
22.71
25.98
25.8
27.1
25.84
Tangible Book Value per Share
135
135
135
100
101
118
135
134
134
132
130
130
Basic Weighted Avg Shares
71
93
262
559
555
1,039
1,292
1,447
1,577
1,432
1,165
1,210
Sales/Revenue/Turnover
38.66
29.82
36.17
35.18
40.66
45.33
48.83
45.74
38.77
38.49
23.44
24.36
Operating Margin (%)
10
10
10
9
9
12
17
33
51
65
77
- -
Depreciation Expense
12
7
74
154
187
408
829
598
509
399
220
258
Net Income, GAAP
21.61
6.47
18.07
18.63
16.41
15.68
9.4
12.54
11.29
14.64
15.34
13.15
Effective Tax Rate (%)
16.47
7.17
28.43
27.55
33.66
39.29
64.18
41.34
32.28
27.84
18.88
21.33
Profit Margin (%)
-185
-171
124
276
464
1,609
1,604
1,533
1,975
1,922
2,084
2,301
Working Capital
- -
- -
- -
- -
- -
- -
- -
16
- -
- -
- -
3
LT Debt
-103
-96
188
368
575
1,974
2,670
3,076
3,514
3,448
3,537
3,931
Total Equity
- -
- -
141.43
51.68
37.33
31.54
35.41
20.41
14.88
10.97
6.11
6.6
Return on Invested Capital (%)
- -
-16.19
157.85
53.04
38.53
31.91
35.71
20.46
14.87
10.99
6.1
6.89
Return on Capital (%)
- -
- -
- -
55.44
39.62
32.02
35.72
20.82
15.45
11.45
6.3
7.24
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
30
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
130
130
130
Market Capitalization
7,391
6,180
7,324

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,434
2,469
2,659
Cash, Cash Equivalents & STI
1,055
1,033
1,188
Accounts Receivable, Net
1,194
1,293
1,337
Inventories
151
130
120
Total Current Liabilities
309
323
358
Payables & Accruals
- -
- -
- -
ST Debt
30
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.82%
13.08%
2.61%
Free Cash Flow
1,076.84%
-93.68%
-27.81%
Net Income, GAAP
121.59%
-1.21%
-44.84%
Sales/Revenue/Turnover
43.02%
3.51%
-18.64%
Total Cash Common Dividend
- -
7,825.08%
-49.06%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
311
430
319
371
1,432
2025
138
346
- -
325
1,165
2026
172
366
346
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.12
1.19
0.76
-0.06
3.03
2025
0.16
0.72
- -
0.24
1.69
2026
0.21
0.88
0.66
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
1.97
- -
0.04
2.03
2025
0.03
1.01
- -
0.01
1.05
2026
- -
0.5
- -
- -
- -
Business
Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) engages in the research, development, production, sale, and technical services of preventive biological products, primarily human vaccines, from its headquarters at No. 182 Beijing Road in Chengdu Economic and Technological Development Zone, China, where it was founded in 2004. The company operates GMP-certified facilities including a world-class biotechnology experimental center, SPF experimental animal center, and high-tech workshops for bacterial and viral vaccines, serving domestic markets with nationwide distribution and select exports. Its core marketed products comprise Group ACYW135 Meningococcal Polysaccharide Vaccine (Maikexin) for preventing meningococcal disease; freeze-dried Rabies Vaccine (human diploid cell, HDCV), China's first domestically developed premium rabies vaccine with over a decade of safe use; alongside an advancing pipeline featuring recombinant hexavalent norovirus vaccine (licensed overseas to HilleVax), tetravalent influenza vaccine in clinical stages, herpes zoster vaccine in preclinical development, and others across prophylactic, mRNA, conjugated, inactivated, and polysaccharide categories. In July 2025, Shanghai Healthcare M&A Fund, managed by SIIC Capital, announced a strategic agreement to acquire the company, aiming to accelerate sales of mature products like the rabies vaccine, expand the diversified vaccine pipeline, integrate Shanghai's R&D resources with Chengdu's manufacturing strengths, and establish a fully integrated vaccine ecosystem through commercialization and innovation synergies; additionally, Shanghai Wankexin Biotechnology Partnership signed a share transfer agreement for a 21.91% stake. Kanghua maintains over 100 patented technologies, has undertaken multiple scientific projects, and holds certifications from China's National Medical Products Administration, positioning it as a key player in China's biopharmaceutical sector focused on high-barrier public health vaccines.